Albumin fusion proteins
First Claim
1. An albumin fusion protein comprising an exendin-4 polypeptide fused to an albumin polypeptide, wherein said exendin-4 polypeptide is selected from:
- (a) a full-length exendin-4;
(b) a mature exendin-4;
(c) a fragment of exendin-4, wherein said fragment has exendin-4 activity;
(d) a polypeptide consisting of an amino acid sequence at least 90% identical to exendin-4, wherein said polypeptide has exendin-4 activity;
(e) a polypeptide consisting of an amino acid sequence at least 95% identical to exendin-4, wherein said polypeptide has exendin-4 activity;
(f) a polypeptide consisting of an amino acid sequence at least 99% identical to exendin-4, wherein said polypeptide has exendin-4 activity;
(g) a polypeptide comprising amino acids 1 to 87 of SEQ ID NO;
635;
(h) a polypeptide comprising amino acids 48 to 86 of SEQ ID NO;
635; and
wherein said albumin polypeptide is selected from;
(i) a full-length albumin;
(ii) a mature albumin;
(iii) a fragment of albumin, wherein said fragment of albumin has the ability to prolong the serum half-life of the exendin-4 polypeptide;
(iv) a polypeptide consisting of an amino acid sequence at least 95% identical to albumin, wherein said polypeptide has the ability to prolong the serum half-life of the exendin-4 polypeptide;
(v) amino acids 1 to 585 of SEQ ID NO;
1038; and
(vi) amino acids 1 to 387 of SEQ ID NO;
1038.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
130 Citations
20 Claims
-
1. An albumin fusion protein comprising an exendin-4 polypeptide fused to an albumin polypeptide, wherein said exendin-4 polypeptide is selected from:
-
(a) a full-length exendin-4;
(b) a mature exendin-4;
(c) a fragment of exendin-4, wherein said fragment has exendin-4 activity;
(d) a polypeptide consisting of an amino acid sequence at least 90% identical to exendin-4, wherein said polypeptide has exendin-4 activity;
(e) a polypeptide consisting of an amino acid sequence at least 95% identical to exendin-4, wherein said polypeptide has exendin-4 activity;
(f) a polypeptide consisting of an amino acid sequence at least 99% identical to exendin-4, wherein said polypeptide has exendin-4 activity;
(g) a polypeptide comprising amino acids 1 to 87 of SEQ ID NO;
635;
(h) a polypeptide comprising amino acids 48 to 86 of SEQ ID NO;
635; and
wherein said albumin polypeptide is selected from;
(i) a full-length albumin;
(ii) a mature albumin;
(iii) a fragment of albumin, wherein said fragment of albumin has the ability to prolong the serum half-life of the exendin-4 polypeptide;
(iv) a polypeptide consisting of an amino acid sequence at least 95% identical to albumin, wherein said polypeptide has the ability to prolong the serum half-life of the exendin-4 polypeptide;
(v) amino acids 1 to 585 of SEQ ID NO;
1038; and
(vi) amino acids 1 to 387 of SEQ ID NO;
1038. - View Dependent Claims (2, 3, 4, 5, 6, 16, 17, 18, 19, 20)
-
-
7. A nucleic acid molecule comprising a first polynucleotide and a second polynucleotide, wherein said first polynucleotide encodes an exendin-4 polypeptide selected from:
-
(a) a full-length exendin-4;
(b) a mature exendin-4;
(c) a fragment of exendin-4, wherein said fragment has exendin-4 activity;
(d) a polypeptide consisting of an amino acid sequence at least 90% identical to exendin-4, wherein said polypeptide has exendin-4 activity;
(e) a polypeptide consisting of an amino acid sequence at least 95% identical to exendin-4, wherein said polypeptide has exendin-4 activity;
(f) a polypeptide consisting of an amino acid sequence at least 99% identical to exendin-4, wherein said polypeptide has exendin-4 activity;
(g) a polypeptide comprising amino acids 1 to 87 of SEQ ID NO;
635;
(h) a polypeptide comprising amino acids 48 to 86 of SEQ ID NO;
635; and
wherein said second polynucleotide encodes an albumin polypeptide selected from;
(i) a full-length albumin;
(ii) a mature albumin;
(iii) a fragment of albumin, wherein said fragment of albumin has the ability to prolong the serum half-life of the exendin-4 polypeptide;
(iv) a polypeptide consisting of an amino acid sequence at least 95% identical to albumin, wherein said polypeptide has the ability to prolong the serum half-life of the exendin-4 polypeptide;
(v) amino acids 1 to 585 of SEQ ID NO;
1038; and
(vi) amino acids 1 to 387 of SEQ ID NO;
1038. - View Dependent Claims (8, 9, 10, 11, 12, 13, 14, 15)
-
Specification